

29th October, 2026

To, The Secretary, Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code - 543308 ISIN: INE967H01025	To, The Secretary, National Stock Exchange (NSE), Exchange Plaza, 5 th Floor Plot No.C/1, 'G' Block Bandra - Kurla Complex Mumbai - 400 051. Symbol - KIMS
--	--

Dear Sir/ Madam

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Acquisition of 5.82% stake in Ushahkal Abhinav Specialty Hospital LLP (Sangli)– Reg.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and pursuant to the resolution adopted by the board of directors of Krishna Institute of Medical Sciences Limited (KIMS) wherein the Board of Directors had approved the proposal for acquisition of up to 6.00% stake in Ushahkal Abhinav Specialty Hospital LLP (Sangli), an O&M entity, for an aggregate consideration of up to ₹15.00 crore, today the Company has entered into definitive agreements in connection with the proposed acquisition and has remitted the consideration towards the acquisition.

We enclose herewith the details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 as an **Annexure-1** to this letter.

Kindly take the above intimation on your records. This intimation is also uploaded on the Company's website at: <https://www.kimshospitals.com/investors/> > **Disclosures under Regulation 62 of the SEBI (LODR) Regulations, 2015 > Intimations filed by the Company > Intimations under Regulation 30.**

Thanking You,

Yours truly

For Krishna Institute of Medical Sciences Limited

NAGAJAYANT
HI JUTTUR
RAGHAVENDR
A DAS

Digitally signed by
NAGAJAYANTHI JUTTUR
RAGHAVENDRA DAS
Date: 2026.10.29
21:56:42 +05'30'

Nagajayanthi J.R

Company Secretary and Compliance Officer

Krishna Institute of Medical Sciences Limited

D.No.: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India
Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com
CIN: L55101TG1973PLC040558

ANNEXURE -1

a	Name of the target entity, details in brief such as size, turnover, etc.,	Name of the target entity: Ushahkal Abhinav Specialty Hospital LLP. <u>Details in brief:</u> Ushahkal Abhinav Speciality Hospital LLP, (UAIMS) incorporated under the laws of India with its registered office at C. S. No. 105/1, Near Takshila School, Dhamani Road, Sangli – 416416 (Maharashtra), founded in 2022, is a state-of-the-art quaternary care facility with a current capacity of 316 beds and potential for expansion to over 500 beds. Spanning 4 acres, it boasts one of the highest floor-area-to-bed ratios in the region. (Rs. in Crore) <table><tr><th colspan="2">FY 2025-26</th></tr><tr><td>Turnover:</td><td>80.42</td></tr><tr><td>PAT:</td><td>-23.59</td></tr><tr><td>Networth:</td><td>116.42</td></tr></table>	FY 2025-26		Turnover:	80.42	PAT:	-23.59	Networth:	116.42
FY 2025-26										
Turnover:	80.42									
PAT:	-23.59									
Networth:	116.42									
b	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of Interest and details thereof and whether the same is done at "Arms length":	The Transaction does not fall under a related party transaction.								
c	Industry to which the entity being acquired belongs:	Healthcare Industry								
d	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity	KIMS has acquired 5.82% of the total stake as a strategic investment.								
e	Brief details of any governmental or regulatory approvals required for the acquisition:	Not Applicable.								
f	Indicative time period for completion of the acquisition	Not Applicable								

g	Consideration - whether cash consideration or share swap and details of the same:	Cash.								
h	Cost of acquisition or the price at which the shares are acquired;	The acquisition was based on the valuation report issued by BDO Valuation Advisory LLP, dated 05 th October, 2026, for an aggregate consideration up to ₹15 Crore (Rupees Fifteen Crore only) by way of primary infusion, for 5.82% stake of the target LLP.								
i	Percentage of shareholding/control acquired and/or number of shares acquired;	KIMS has acquired 5.82% of the stake of Target LLP, for an aggregate consideration of ₹15 Crore (Rupees Fifteen Crore only) by way of primary infusion.								
j	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence, and any other significant information (in brief):	Brief background about the entity acquired: As mentioned in serial no. (a) Date of Incorporation of LLP: 25-11-2016 History of last 3 years Total Turnover of the Company: <table border="1"><thead><tr><th>Particulars</th><th>Amount in Crores</th></tr></thead><tbody><tr><td>FY26</td><td>80.42</td></tr><tr><td>FY25</td><td>73.55</td></tr><tr><td>FY24</td><td>64.51</td></tr></tbody></table> Presence: Sangli, Maharashtra - India Other Significant Information: please refer to the aforementioned.	Particulars	Amount in Crores	FY26	80.42	FY25	73.55	FY24	64.51
Particulars	Amount in Crores									
FY26	80.42									
FY25	73.55									
FY24	64.51									